Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                        1.1.1. Regional Scope
                        1.1.2. Estimates And Forecast Timeline
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources
                        1.3.4. Primary Research
                        1.3.5. Details Of Primary Research
                    1.4. Information Or Data Analysis
                        1.4.1. Data Analysis Models
                    1.5. Market Formulation & Validation
                        1.5.1. Region Wise Market: Base Estimates
                        1.5.2. Global Market: CAGR Calculation
                    1.6. Model Details
                        1.6.1. Commodity Flow Analysis (Model 1)
                        1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
                        1.6.3. QFD Model Sizing & Forecasting (Model 3)
                        1.6.4. Bottom-Up Approach (Model 4)
                    1.7. Market Definitions
                    1.8. List Of Secondary Sources
                    1.9. List Of Abbreviations
                    1.10. Objectives
                        1.10.1. Objective - 1
                        1.10.2. Objective - 2
                        1.10.3. Objective - 3
                        1.10.4. Objective - 4
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Ancillary Market Outlook
                    3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
                        3.2.1. Market Driver Impact Analysis
                            3.2.1.1. Rising Adoption Of Biologics And Biosimilars
                            3.2.1.2. Technological Innovations Pertaining To The Development Of Novel Recombinant Protein Therapeutics
                            3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Regulatory Hurdles
                            3.2.2.2. Challenges Related To Quality Control
                    3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
                        3.3.1. Porter’s Five Forces Analysis
                        3.3.2. PESTEL Analysis
                    3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
                    3.5. Covid-19 Impact On Bioprocessing And Outsourcing
                        3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
                        3.5.2. Supply Chain
                        3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
                        3.5.4. Changes In The Long Term
Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
                    4.3. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
                        4.3.1. Growth Hormones
                            4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        4.3.2. Interferons
                            4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        4.3.3. Vaccines
                            4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        4.3.4. Immunostimulating Agents
                            4.3.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        4.3.5. Others
                            4.3.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
                    5.3. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
                        5.3.1. Mammalian Systems
                            5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        5.3.2. Microbial Systems
                            5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        5.3.3. Others
                            5.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
                    6.3. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
                        6.3.1. Oncology
                            6.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.2. Infectious Diseases
                            6.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.3. Immunological Disorders
                            6.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.4. Metabolic Disorders
                            6.3.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.5. Hematological Disorders
                            6.3.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.6. Others
                            6.3.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Recombinant Protein Therapeutics CDMO Market: Service Type Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
                    7.3. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
                        7.3.1. Contract Manufacturing
                            7.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        7.3.2. Contract Development
                            7.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. Recombinant Protein Therapeutics CDMO Market: End Use Estimates & Trend Analysis
                    8.1. Segment Dashboard
                    8.2. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
                    8.3. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
                        8.3.1. Pharmaceutical Companies
                            8.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        8.3.2. Biotech Companies
                            8.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        8.3.3. Others
                            8.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 9. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication, Service Type, End Use
                    9.1. Regional Market Dashboard
                    9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                    9.3. North America
                        9.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.3.2. U.S.
                            9.3.2.1. Key Country Dynamics
                            9.3.2.2. Competitive Scenario
                            9.3.2.3. Regulatory Scenario
                            9.3.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.3.3. Canada
                            9.3.3.1. Key Country Dynamics
                            9.3.3.2. Competitive Scenario
                            9.3.3.3. Regulatory Scenario
                            9.3.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.3.4. Mexico
                            9.3.4.1. Key Country Dynamics
                            9.3.4.2. Competitive Scenario
                            9.3.4.3. Regulatory Scenario
                            9.3.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    9.4. Europe
                        9.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.2. UK
                            9.4.2.1. Key Country Dynamics
                            9.4.2.2. Competitive Scenario
                            9.4.2.3. Regulatory Scenario
                            9.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.3. Germany
                            9.4.3.1. Key Country Dynamics
                            9.4.3.2. Competitive Scenario
                            9.4.3.3. Regulatory Scenario
                            9.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.4. France
                            9.4.4.1. Key Country Dynamics
                            9.4.4.2. Competitive Scenario
                            9.4.4.3. Regulatory Scenario
                            9.4.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.5. Italy
                            9.4.5.1. Key Country Dynamics
                            9.4.5.2. Competitive Scenario
                            9.4.5.3. Regulatory Scenario
                            9.4.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.6. Spain
                            9.4.6.1. Key Country Dynamics
                            9.4.6.2. Competitive Scenario
                            9.4.6.3. Regulatory Scenario
                            9.4.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.7. Denmark
                            9.4.7.1. Key Country Dynamics
                            9.4.7.2. Competitive Scenario
                            9.4.7.3. Regulatory Scenario
                            9.4.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.8. Sweden
                            9.4.8.1. Key Country Dynamics
                            9.4.8.2. Competitive Scenario
                            9.4.8.3. Regulatory Scenario
                            9.4.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.4.9. Norway
                            9.4.9.1. Key Country Dynamics
                            9.4.9.2. Competitive Scenario
                            9.4.9.3. Regulatory Scenario
                            9.4.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    9.5. Asia Pacific
                        9.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.2. Japan
                            9.5.2.1. Key Country Dynamics
                            9.5.2.2. Competitive Scenario
                            9.5.2.3. Regulatory Scenario
                            9.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.3. China
                            9.5.3.1. Key Country Dynamics
                            9.5.3.2. Competitive Scenario
                            9.5.3.3. Regulatory Scenario
                            9.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.4. India
                            9.5.4.1. Key Country Dynamics
                            9.5.4.2. Competitive Scenario
                            9.5.4.3. Regulatory Scenario
                            9.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.5. Australia
                            9.5.5.1. Key Country Dynamics
                            9.5.5.2. Competitive Scenario
                            9.5.5.3. Regulatory Scenario
                            9.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.6. Thailand
                            9.5.6.1. Key Country Dynamics
                            9.5.6.2. Competitive Scenario
                            9.5.6.3. Regulatory Scenario
                            9.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.5.7. South Korea
                            9.5.7.1. Key Country Dynamics
                            9.5.7.2. Competitive Scenario
                            9.5.7.3. Regulatory Scenario
                            9.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    9.6. Latin America
                        9.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.6.2. Brazil
                            9.6.2.1. Key Country Dynamics
                            9.6.2.2. Competitive Scenario
                            9.6.2.3. Regulatory Scenario
                            9.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.6.3. Argentina
                            9.6.3.1. Key Country Dynamics
                            9.6.3.2. Competitive Scenario
                            9.6.3.3. Regulatory Scenario
                            9.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    9.7. MEA
                        9.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.7.2. South Africa
                            9.7.2.1. Key Country Dynamics
                            9.7.2.2. Competitive Scenario
                            9.7.2.3. Regulatory Scenario
                            9.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.7.3. Saudi Arabia
                            9.7.3.1. Key Country Dynamics
                            9.7.3.2. Competitive Scenario
                            9.7.3.3. Regulatory Scenario
                            9.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.7.4. UAE
                            9.7.4.1. Key Country Dynamics
                            9.7.4.2. Competitive Scenario
                            9.7.4.3. Regulatory Scenario
                            9.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        9.7.5. Kuwait
                            9.7.5.1. Key Country Dynamics
                            9.7.5.2. Competitive Scenario
                            9.7.5.3. Regulatory Scenario
                            9.7.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
                    10.1. Company Categorization
                    10.2. Recombinant Protein Therapeutics CDMO Market Share/Assesment Analysis, 2023
                    10.3. Company Profiles
                        10.3.1. Richter-Helm BioLogics
                            10.3.1.1. Company overview
                            10.3.1.2. Financial performance
                            10.3.1.3. Product benchmarking
                            10.3.1.4. Strategic initiatives
                        10.3.2. Lonza
                            10.3.2.1. Company overview
                            10.3.2.2. Financial performance
                            10.3.2.3. Product benchmarking
                            10.3.2.4. Strategic initiatives
                        10.3.3. Catalent, Inc
                            10.3.3.1. Company overview
                            10.3.3.2. Financial performance
                            10.3.3.3. Product benchmarking
                            10.3.3.4. Strategic initiatives
                        10.3.4. FUJIFILM Diosynth Biotechnologies
                            10.3.4.1. Company overview
                            10.3.4.2. Financial performance
                            10.3.4.3. Product benchmarking
                            10.3.4.4. Strategic initiatives
                        10.3.5. WuXi Biologics
                            10.3.5.1. Company overview
                            10.3.5.2. Financial performance
                            10.3.5.3. Product benchmarking
                            10.3.5.4. Strategic initiatives
                        10.3.6. Curia Global, Inc.
                            10.3.6.1. Company overview
                            10.3.6.2. Financial performance
                            10.3.6.3. Product benchmarking
                            10.3.6.4. Strategic initiatives
                        10.3.7. Batavia Biosciences B.V.
                            10.3.7.1. Company overview
                            10.3.7.2. Financial performance
                            10.3.7.3. Product benchmarking
                            10.3.7.4. Strategic initiatives
                        10.3.8. HALIX B.V.
                            10.3.8.1. Company overview
                            10.3.8.2. Financial performance
                            10.3.8.3. Product benchmarking
                            10.3.8.4. Strategic initiatives
                        10.3.9. BIOVIAN
                            10.3.9.1. Company overview
                            10.3.9.2. Financial performance
                            10.3.9.3. Product benchmarking
                            10.3.9.4. Strategic initiatives
                        10.3.10. Enzene Biosciences Ltd
                            10.3.10.1. Company overview
                            10.3.10.2. Financial performance
                            10.3.10.3. Product benchmarking
                            10.3.10.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 4 Global Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 5 Global Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 6 Global Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 7 Global Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 8 Global Recombinant Protein Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
Table 9 North America Recombinant Protein Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 10 North America Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 11 North America Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 12 North America Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 13 North America Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 14 North America Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 15 U.S. Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 16 U.S. Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 17 U.S. Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 18 U.S. Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 19 U.S. Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 20 Canada Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 21 Canada Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 22 Canada Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 23 Canada Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 24 Canada Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 25 Mexico Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 26 Mexico Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 27 Mexico Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 28 Mexico Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 29 Mexico Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 30 Europe Recombinant Protein Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 31 Europe Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 32 Europe Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 33 Europe Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 34 Europe Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 35 Europe Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 36 Germany Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 37 Germany Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 38 Germany Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 39 Germany Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 40 Germany Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 41 UK Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 42 UK Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 43 UK Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 44 UK Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 45 UK Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 46 France Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 47 France Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 48 France Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 49 France Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 50 France Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 51 Italy Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 52 Italy Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 53 Italy Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 54 Italy Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 55 Italy Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 56 Spain Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 57 Spain Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 58 Spain Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 59 Spain Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 60 Spain Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 61 Denmark Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 62 Denmark Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 63 Denmark Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 64 Denmark Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 65 Denmark Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 66 Sweden Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 67 Sweden Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 68 Sweden Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 69 Sweden Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 70 Sweden Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 71 Norway Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 72 Norway Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 73 Norway Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 74 Norway Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 75 Norway Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 76 Asia Pacific Recombinant Protein Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 77 Asia Pacific Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 78 Asia Pacific Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 79 Asia Pacific Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 80 Asia Pacific Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 81 Asia Pacific Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 82 China Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 83 China Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 84 China Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 85 China Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 86 China Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 87 Japan Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 88 Japan Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 89 Japan Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 90 Japan Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 91 Japan Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 92 India Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 93 India Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 94 India Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 95 India Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 96 India Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 97 South Korea Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 98 South Korea Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 99 South Korea Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 100 South Korea Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 101 South Korea Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 102 Australia Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 103 Australia Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 104 Australia Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 105 Australia Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 106 Australia Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 107 Thailand Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 108 Thailand Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 109 Thailand Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 110 Thailand Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 111 Thailand Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 112 Latin America Recombinant Protein Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 113 Latin America Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 114 Latin America Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 115 Latin America Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 116 Latin America Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 117 Latin America Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 118 Brazil Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 119 Brazil Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 120 Brazil Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 121 Brazil Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 122 Brazil Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 123 Argentina Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 124 Argentina Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 125 Argentina Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 126 Argentina Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 127 Argentina Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa Recombinant Protein Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 133 Middle East & Africa Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 134 South Africa Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 135 South Africa Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 136 South Africa Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 137 South Africa Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 138 South Africa Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 143 Saudi Arabia Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 144 UAE Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 145 UAE Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 146 UAE Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 147 UAE Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 148 UAE Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 149 Kuwait Recombinant Protein Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 150 Kuwait Recombinant Protein Therapeutics CDMO, by Source, 2018 - 2030 (USD Million)
Table 151 Kuwait Recombinant Protein Therapeutics CDMO, by Indication, 2018 - 2030 (USD Million)
Table 152 Kuwait Recombinant Protein Therapeutics CDMO, by Service Type, 2018 - 2030 (USD Million)
Table 153 Kuwait Recombinant Protein Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Recombinant Protein Therapeutics CDMO, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 Global Recombinant Protein Therapeutics CDMO,for Growth Hormones, 2018 - 2030 (USD Million)
Fig. 13 Global Recombinant Protein Therapeutics CDMO,for Interferons, 2018 - 2030 (USD Million)
Fig. 14 Global Recombinant Protein Therapeutics CDMO,for Vaccines, 2018 - 2030 (USD Million)
Fig. 15 Global Recombinant Protein Therapeutics CDMO,for Immunostimulating Agents, 2018 - 2030 (USD Million)
Fig. 16 Global Recombinant Protein Therapeutics CDMO,for Others, 2018 - 2030 (USD Million)
Fig. 17 Global Recombinant Protein Therapeutics CDMO,for Mammalian Systems, 2018 - 2030 (USD Million)
Fig. 18 Global Recombinant Protein Therapeutics CDMO,for Microbial Systems, 2018 - 2030 (USD Million)
Fig. 19 Global Recombinant Protein Therapeutics CDMO,for Others, 2018 - 2030 (USD Million)
Fig. 20 Global Recombinant Protein Therapeutics CDMO,for Oncology, 2018 - 2030 (USD Million)
Fig. 21 Global Recombinant Protein Therapeutics CDMO,for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 22 Global Recombinant Protein Therapeutics CDMO,for Immunological Disorders, 2018 - 2030 (USD Million)
Fig. 23 Global Recombinant Protein Therapeutics CDMO,for Metabolic Disorders, 2018 - 2030 (USD Million)
Fig. 24 Global Recombinant Protein Therapeutics CDMO,for Hematological Disorders, 2018 - 2030 (USD Million)
Fig. 25 Global Recombinant Protein Therapeutics CDMO,for Others, 2018 - 2030 (USD Million)
Fig. 26 Global Recombinant Protein Therapeutics CDMO,for Contract Manufacturing, 2018 - 2030 (USD Million)
Fig. 27 Global Recombinant Protein Therapeutics CDMO,for Contract Development, 2018 - 2030 (USD Million)
Fig. 28 Global Recombinant Protein Therapeutics CDMO,for End Use Outlook (Revenue, USD Million, 2018 - 2030), 2018 - 2030 (USD Million)
Fig. 29 Global Recombinant Protein Therapeutics CDMO,for Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 30 Global Recombinant Protein Therapeutics CDMO,for Biotech Companies, 2018 - 2030 (USD Million)
Fig. 31 Global Recombinant Protein Therapeutics CDMO,for Others, 2018 - 2030 (USD Million)
Fig. 32 Regional Outlook, 2023 & 2030
Fig. 33 North America Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 34 U.S. Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 35 Canada Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 36 Mexico Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Europe Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Germany Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 39 UK Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 40 France Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 41 Italy Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 42 Spain Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 43 Denmark Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 44 Sweden Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 45 Norway Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Asia Pacific Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 Japan Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 China Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 49 India Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 50 Australia Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 51 South Korea Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 52 Thailand Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 53 Latin America Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 54 Brazil Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 55 Argentina Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 56 Middle East and Africa Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 57 South Africa Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 58 Saudi Arabia Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 59 UAE Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 60 Kuwait Recombinant Protein Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)